Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825308 | 0.79 | LMNA (0.41) | LMNAL3MBTL1TRPA1PTGS1CACNA1C | |
| SCHEMBL10147112 | 0.78 | PPIA (0.33) | LMNAL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL19543369 | 0.71 | LMNA (0.40) | LMNATRPA1PTGS1CACNA1CBCHE | |
| SCHEMBL22425679 | 0.66 | LMNA (0.39) | LMNATRPA1PTGS1CACNA1CBCHE | |
| SCHEMBL17707913 | 0.65 | DYRK1A (0.50) | LMNATRPA1PTGS1CACNA1CHDAC4 | |
| SCHEMBL4456649 | 0.63 | LMNA (0.50) | LMNATRPA1PTGS1CACNA1CBCHE | |
| SCHEMBL6939847 | 0.62 | HTR2A (0.42) | LMNASMN1; SMN2KDM4ETSHR | |
| SCHEMBL8715984 | 0.62 | HTR2A (0.42) | LMNASMN1; SMN2KDM4ETSHR | |
| Hydrochloric Acid SCHEMBL4633578 | 0.61 | HTR2A (0.38) | — | |
| SCHEMBL4586061 | 0.60 | HTR7 (0.43) | LMNATRPA1PTGS1CACNA1CHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | LMNA 821/4885L3MBTL1 169/4885TRPA1 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.